GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » Degree of Financial Leverage

Generex Biotechnology (Generex Biotechnology) Degree of Financial Leverage : 0.00 (As of Apr. 2021)


View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Generex Biotechnology's Degree of Financial Leverage for the quarter that ended in Apr. 2021 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Generex Biotechnology's Degree of Financial Leverage or its related term are showing as below:

GNBTQ's Degree of Financial Leverage is not ranked *
in the Biotechnology industry.
Industry Median: 0.97
* Ranked among companies with meaningful Degree of Financial Leverage only.

Generex Biotechnology Degree of Financial Leverage Historical Data

The historical data trend for Generex Biotechnology's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology Degree of Financial Leverage Chart

Generex Biotechnology Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Generex Biotechnology Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Generex Biotechnology's Degree of Financial Leverage

For the Biotechnology subindustry, Generex Biotechnology's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generex Biotechnology's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generex Biotechnology's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Generex Biotechnology's Degree of Financial Leverage falls into.



Generex Biotechnology Degree of Financial Leverage Calculation

Generex Biotechnology's Degree of Financial Leverage for the quarter that ended in Apr. 2021 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.52 (Apr. 2021) / -0.39 (Apr. 2020) - 1 )/( -34.48 (Apr. 2021) / -19.656 (Apr. 2020) - 1 )
=0.3333/0.7542
=0.44***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Generex Biotechnology  (OTCPK:GNBTQ) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Generex Biotechnology Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Generex Biotechnology (Generex Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10102 USA Today Way, Miramar, FL, USA, 33025
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.
Executives
Prioletti Mark Joseph Se director 1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr director 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines other: Consultant 11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher officer: EVP General Counsel &Secretary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee director 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr. director 33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao officer: CFO & Treasurer 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr. director, officer: SVP of Research & Drug Develop 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman director 10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti director 10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro director, officer: SVP & Chief Investment Officer 10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard officer: Chief Operating Officer 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows officer: Chief Financial Officer 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von director, officer: President of Subsidiary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt director 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1

Generex Biotechnology (Generex Biotechnology) Headlines

From GuruFocus